Galectin Therapeutics Inc.
NASDAQ:GALT · NASDAQ Capital Market
+$0.05 today
Vol 0.26M · Avg 0.32M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:GALT · Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$26.3M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-0.41, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 | $725.6M | $804.0M | $882.4M |
| Gross Profit | $0 | $0 | $0 | $0 | $0 | $8.9B | $7.6B | $6.2B |
| Gross Margin | — | — | — | — | — | 9.8% | 28.9% | 38.3% |
| Research & Development | $14.3M -60.9% | $36.6M +13.8% | $32.1M +1.2% | $31.7M +33.2% | $23.8M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $5.8M -1.1% | $5.9M -1.3% | $5.9M -10.2% | $6.6M +4.0% | $6.4M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $20.1M -52.7% | $42.4M +11.5% | $38.1M -0.7% | $38.4M +27.1% | $30.2M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $53.0K +43.2% | $37.0K +12.1% | $33.0K +3.1% | $32.0K -22.0% | $41.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$23.5M +43.4% | -$41.5M -8.4% | -$38.2M -1.4% | -$37.7M -25.7% | -$30.0M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | — | — | — | — | — | 5.6% | 46.3% | 42.0% |
| Operating Income | -$20.1M +52.7% | -$42.4M -11.5% | -$38.1M +0.7% | -$38.4M -27.1% | -$30.2M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | — | — | — | — | — | 16.6% | 24.1% | 22.0% |
| Interest Income | $126.0K -62.7% | $338.0K +47.0% | $230.0K +342.3% | $52.0K +1633.3% | $3.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $7.3M +32.3% | $5.5M +98.4% | $2.8M +170.3% | $1.0M +111.2% | $489.0K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$10.8M -133.0% | -$4.6M -54.1% | -$3.0M -606.1% | -$424.0K -21.8% | -$348.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$30.8M +34.5% | -$47.0M -14.6% | -$41.1M -5.9% | -$38.8M -27.0% | -$30.5M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | — | — | — | — | — | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$30.8M +34.5% | -$47.0M -14.6% | -$41.1M -5.9% | -$38.8M -27.0% | -$30.5M | $4.9B | $4.8B | $4.7B |
| Net Margin | — | — | — | — | — | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$0 +36.8% | -$1 -2.7% | -$1 -13.8% | -$1 -25.0% | -$1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$0 +36.8% | -$1 -2.7% | -$1 -13.8% | -$1 -25.0% | -$1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $63.9M +2.6% | $62.3M +3.6% | $60.2M +1.3% | $59.4M +1.5% | $58.5M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $63.9M +2.6% | $62.3M +3.6% | $60.2M +1.3% | $59.4M +1.5% | $58.5M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Alpha Tau Medical Ltd.
NASDAQ:DRTS
$860.81M
LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRX
$852.56M
Design Therapeutics, Inc.
NASDAQ:DSGN
$766.98M
Aura Biosciences, Inc.
NASDAQ:AURA
$398.04M
Rocket Pharmaceuticals, Inc.
NASDAQ:RCKT
$355.17M
DiaMedica Therapeutics Inc.
NASDAQ:DMAC
$307.67M
Altimmune, Inc.
NASDAQ:ALT
$240.50M
I-Mab
IMAB
$235.66M
Quantum-Si incorporated
NASDAQ:QSI
$196.70M
enGene Holdings Inc.
NASDAQ:ENGN
$88.06M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does GALT generate?
Galectin Therapeutics Inc. (GALT) reported $0.00 of revenue in fiscal 2025.
Is GALT profitable?
Galectin Therapeutics Inc. (GALT) reported -$30,836,000.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.